ConvaTec Group PLC (LON:CTEC) Receives GBX 318.67 Average Price Target from Analysts

ConvaTec Group PLC (LON:CTEC) has been assigned a consensus recommendation of “Buy” from the six ratings firms that are covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have issued a report on the stock in the last year is GBX 318.67.

A number of brokerages recently commented on CTEC. UBS Group reiterated a “buy” rating and issued a GBX 375 price objective on shares of ConvaTec Group in a research report on Friday, November 7th. Peel Hunt reaffirmed an “add” rating and issued a GBX 270 target price on shares of ConvaTec Group in a research note on Thursday, November 13th. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating on shares of ConvaTec Group in a report on Friday, November 14th.

ConvaTec Group Stock Up 2.1%

Shares of CTEC opened at GBX 243 on Friday. The company has a market capitalization of £4.75 billion, a P/E ratio of 22.92, a PEG ratio of 0.93 and a beta of 0.64. ConvaTec Group has a one year low of GBX 218 and a one year high of GBX 311.20. The business’s 50 day simple moving average is GBX 237.53 and its 200-day simple moving average is GBX 242.86. The company has a debt-to-equity ratio of 85.32, a current ratio of 2.26 and a quick ratio of 0.96.

ConvaTec Group Company Profile

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.